Dr. Reddy's Laboratories recorded quarterly earnings of Rs 1,409.6 crore during the first three months of fiscal year 2026. The Hyderabad pharmaceutical company experienced an 11 percent decline from the previous quarter's Rs 1,587.3 crore profit. Annual comparisons showed modest growth of one percent above the Rs 1,392 crore earned during the same period last year. Revenue reached Rs 8,545.2 crore, representing increases from both quarterly and yearly benchmarks. Higher operating costs of Rs 3,115.2 crore contributed to reduced profit margins.
Co-Chairman GV Prasad highlighted strong performance in branded markets and nicotine replacement therapy products. The executive warned about mounting pricing pressures affecting Lenalidomide sales within American generic drug markets. Dr. Reddy's strengthened its biosimilar development through expanded collaboration with Alvotech on pembrolizumab manufacturing. The company introduced Sensimune, targeting dust mite allergies in Indian markets. Share prices advanced 0.65 percent to close Wednesday trading at Rs 1,248.
Co-Chairman GV Prasad highlighted strong performance in branded markets and nicotine replacement therapy products. The executive warned about mounting pricing pressures affecting Lenalidomide sales within American generic drug markets. Dr. Reddy's strengthened its biosimilar development through expanded collaboration with Alvotech on pembrolizumab manufacturing. The company introduced Sensimune, targeting dust mite allergies in Indian markets. Share prices advanced 0.65 percent to close Wednesday trading at Rs 1,248.
